Assuntos
Neoplasias da Mama/diagnóstico por imagem , COVID-19 , Biópsia Guiada por Imagem/estatística & dados numéricos , Mamografia/estatística & dados numéricos , Ultrassonografia Mamária/estatística & dados numéricos , Agendamento de Consultas , Neoplasias da Mama/patologia , Neoplasias da Mama/cirurgia , Procedimentos Cirúrgicos Eletivos , Feminino , Florida , Humanos , Imageamento por Ressonância Magnética/estatística & dados numéricosRESUMO
Bilateral whole breast (screening) ultrasound has been well established in multiple single- and multi-institution published studies as a valuable adjunct to mammography screening for early detection of breast cancer. However, implementation of screening breast ultrasound programs has been limited and has met with resistance because of the number of potential false positives generated by ultrasound screening, and the lack of available personnel to perform the examination. Automated breast ultrasound, which has recently been approved by the US Food and Drug Administration for use in whole-breast ultrasound screening, is a potential option for providing breast ultrasound screening on a widespread basis.
Assuntos
Automação , Neoplasias da Mama/diagnóstico por imagem , Ultrassonografia Mamária/métodos , Neoplasias da Mama/patologia , Detecção Precoce de Câncer , Desenho de Equipamento , Feminino , Humanos , Mamografia , Programas de Rastreamento , Reprodutibilidade dos Testes , Ultrassonografia Mamária/instrumentação , Estados Unidos , United States Food and Drug AdministrationRESUMO
Neurofibromas are slow-growing, painless, benign nerve-sheath tumors. They occur most commonly in the dermis and subcutis and are rarely found in the breast. We report a rare case of a solitary neurofibroma of the breast in a 61-year-old asymptomatic woman.
RESUMO
Screening mammography can detect breast cancer before it becomes clinically apparent. However, the screening process identifies many false-positive findings for each cancer eventually confirmed. Additional tools are available to help differentiate spurious findings from real ones and to help determine when tissue sampling is required, when short-term follow-up will suffice, or whether the finding can be dismissed as benign. These tools include additional diagnostic mammographic views, breast ultrasound, breast MRI, and, when histologic evaluation is required, percutaneous biopsy. The imaging evaluation of a finding detected at screening mammography proceeds most efficiently, cost-effectively, and with minimization of radiation dose when approached in an evidence-based manner. The appropriateness of the above-referenced tools is presented here as they apply to a variety of findings often encountered on screening mammography; an algorithmic approach to workup of these potential scenarios is also included. The recommendations put forth represent a compilation of evidence-based data and expert opinion of the ACR Appropriateness Criteria(®) Expert Panel on Breast Imaging.
Assuntos
Neoplasias da Mama/diagnóstico , Diagnóstico por Imagem/normas , Fidelidade a Diretrizes/normas , Programas de Rastreamento/normas , Guias de Prática Clínica como Assunto , Biópsia/normas , Neoplasias da Mama/patologia , Calcinose/diagnóstico , Diagnóstico Diferencial , Medicina Baseada em Evidências , Feminino , Humanos , Imageamento por Ressonância Magnética/normas , Mamografia/normas , Palpação , Padrões de Prática Médica , Doses de Radiação , Sociedades Médicas , Ultrassonografia Mamária/normas , Estados UnidosRESUMO
Infantile myofibromatosis is the most common fibrous disorder of infancy and early childhood. Intracranial involvement is rare, with the majority of lesions being localized to the skull or dura with variable intracranial extension. We present the case of a 19-month-old girl with infantile myofibromatosis and an incidentally discovered, enlarging, calcified, posterior fossa mass. The patient underwent suboccipital craniotomy and resection of the lesion. This is the first report of the surgical removal of an intraparenchymal infantile myofibroma.